Clinical trial
A Prospective Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of Rentosertib (INS018_055) Administered Orally Over 52 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT07687459 is registered in ClinicalTrials.gov with InSilico Medicine Hong Kong Limited as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Prospective Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study Evaluating the Efficacy and Safety of Rentosertib (INS018_055) Administered Orally Over 52 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Lead sponsor
- InSilico Medicine Hong Kong Limited
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- September 9, 2026
- Completion date
- October 30, 2029
- Enrollment
- 320 (estimated)
- Sites
- 47
Conditions
As the registry lists them; a condition with its own page is linked.